問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of Infectious Disease

更新時間:2025-08-20

蔡明道
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

3Cases

2025-03-31 - 2028-06-30

Active
A retrospective, observational post-marketing study evaluating the efficacy and safety of intravenously administered polymyxin B and colistin methanesulfonate in treating patients with carbapenem-resistant, Gram-negative bacterial infections.
  • Condition/Disease

    1. Clinical response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC (End of Treatment (EOT) + 7 days). 2. Clinical response rate of the two treatment groups at TOC. 3. Microbiological response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC. 4. Microbiological response rate of the two treatment groups at TOC. 5. All-cause mortality rate of the two treatment groups at day 28. 6. Infection-related mortality rate of the two treatment groups at day 28.

  • Test Drug

    POLYMYXIN B SULFATE

Participate Sites
13Sites

Recruiting13Sites

2025-04-29 - 2027-06-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-09-01 - 2026-09-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites